Supplementation of omega-3 fatty acids with aripiprazole and lithium lessens methylphenidate induced manic behavior in Swiss albino mice

PharmaNutrition

Volumn 2, Issue 1, 2014, Pages 26-32

  Arunagiri, Pandiyan ^a   Rajeshwaran, Krishnamoorthy ^a   Shanthakumar, Janakiraman ^a   Balamurugan, Elumalai ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Behavior; Locomotion; Mania; Methylphenidate; Omega 3 fatty acid

Indexed keywords

EID: 84894905412     PISSN: 22134344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phanu.2013.11.128     Document Type: Article

References (63)

1. Kessler R.C., Rubinow D.R., Holmes C., Abelson J.M., Zhao S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychological Medicine 1997, 27:1079-1089.
2. Health Organization World Global burden of disease 2002, World Health Organization, Geneva.
3. Einat H. Modeling facets of mania: new directions related to the notion of endophenotypes. Journal of Psychopharmacology 2006, 20:714-722.
4. Eckermann K., Beasley A., Yang P., Gaytan O., Swann A., Dafny N. Methylphenidate sensitization is modulated by valproate. Life Sciences 2001, 69:47-57.
5. Frey B.N., Andreazza A.C., Ceresér K.M., Martins M.R., Valvassori S.S., Réus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences 2006, 79:281-286.
6. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behavioral Brain Research 2001, 118:95-105.
7. Sabioni P., Baretta I.P., Ninomiya E.M., Gustafson L., Rodrigues A.L., Andreatini R. The antimanic-like effect of tamoxifen: behavioral comparison with other PKC inhibiting and antiestrogenic drugs. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32:1927-1931.
8. Einat H., Yuan P., Szabo S.T., Dogra S., Manji H.K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007, 55:123-131.
9. Smith R.C., Davis J.M. Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man. Psychopharmacology 1977, 33:1-12.
10. Cappeliez P., Moore E. Effects of LiCl on an amphetamine animal model of bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1990, 14:347-358.
11. Gessa G.L., Pani L., Serra G., Fratta W. Animal models of mania. Advances Biochemistry and Psychopharmacology 1995, 49:43-66.
12. Janowsky D.S., El-Yousef M.K., Davis I.M., Scherke J.H. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Archeives in General Psychiatry 1973, 28:185-191.
13. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. American Journal of Psychiatry 1973, 130:61-67.
14. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research 1986, 396:157-198.
15. Lambert P.A., Carraz G., Borselli S., Carrel S. Neuropsychotropic action of a new antiepileptic: Depramide. Annales Medico-psychologiques 1966, 1:707-710.
16. Macritchie K., Geddes J.R., Scott J., Haslam D., de Lima M., Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database of Systematic Reviews 2003, 1:CD004052.
17. McElroy S.L., Keck P.E., Pope H.G., Hudson J.I. Valproate in psychiatric disorders: literature review and clinical guidelines. Journal of Clinical Psychiatry 1989, 50:23-29.
18. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16:695-714.
19. Jeavons P.M. Sodium valproate and neural tube defects. Lancet 1982, 4:1282-1283.
20. Battino P., Dukes G., Perucca E. Anticonvulsants. Meyler's side effects of drugs. An encyclopaedia of adverse reactions and interactions 1996, 182-185. Elsevier, Amsterdam. 14th ed.
21. Leite J.V., Guimarães F.S., Moreira F.A. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. European Journal of Pharmacology 2008, 578:222-227.
22. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
23. Papakostas G.I., Petersen T.J., Kinrys G., Burns A.M., Worthington J.J., Alpert J.E., et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 2005, 66:1326-1330.
24. Simon J.S., Nemeroff C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and non responding patients with major depressive disorder. Journal of Clinical Psychiatry 2005, 66:1216-1220.
25. Marcus R.N., McQuade R.D., Carson W.H., Hennichen D., Fava M., Simon J.S., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2008, 28:156-165.
26. Levant B., Crane J.F., Carlson S.E. Sub-chronic antipsychotic drug treatment does not alter brain phospholipid fatty acid composition in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30:728-732.
27. Stahl S.M., Shelton R.C. Risperidone with and without paroxetine compared with paroxetine alone for bipolar depression. 41st annual meeting of the American College of Neuropsychopharmacology (ACNP) 2001.
28. Katan M.B. Fish and heart disease. New England Journal of Medicine 1995, 332:1024-1025.
29. Wozniak J., Biederman J., Mick E., Waxmonsky J., Hantsoo L., Best C., et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. European Journal of Neuropsychopharmacology 2007, 17:440-447.
30. Mcnamara R.K., Sullivan J., Richtand N.M. Omega-3 fatty acid deficiency augments amphetamine-induced behavioral sensitization in adult mice: prevention by chronic lithium treatment. Journal of Psychiatric Research 2008, 42:458-468.
31. Lehàr J., Krueger A.S., Avery W., Heilbut A.M., Lisa M.J., Price E.R., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology 2009, 7:659-666.
32. Barbosa F.J., Hesse B., de Almeida R.B., Baretta I.P., Boerngen-Lacerda R., Andreatini R. Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania. Pharmacological Reports 2011, 63:64-70.
33. Yang P., Singhal N., Modi G., Swann A., Dafny N. Effects of lithium chloride on induction and expression of methylphenidate sensitization. European Journal of Pharmacology 2001, 426:65-72.
34. Mavrikaki M., Nomikos G.G., Panagis G. Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania. International Journal of Neuropsychopharmacology 2010, 13:541-548.
35. Shin S.S., Dixon C.E. Oral fish oil restores striatal dopamine release after traumatic brain injury. Neuroscience Letters 2011, 496:168-171.
36. Yegen B.C., Alican I., Yalcin A.S., Oktay S. Calcium channel blockers prevent stress induced ulcers in rats. Agents Actions 1992, 35:130-134.
37. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology 1978, 47:379-391.
38. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berlin) 1995, 121:66-72.
39. Detke M.J., Lucki I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behavioral Brain Research 1996, 73:43-46.
40. Gianfrancesco F.D., Sajatovic M., Tafesse E., Wang R.H. Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder. Annals of Clinical Psychiatry 2009, 21:3-16.
41. Yuen A.W.C., Sander J.W., Fluegel D., Patsalos P.N. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behavior 2005, 7:253-258.
42. Mazza M., Pomponi M., Janiri L., Bria P., Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:12-26.
43. Carlezon W.A., Mague S.D., Parow A.M., Stoll A.L., Cohen B.M., Renshaw P.F. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biological Psychiatry 2005, 57:343-350.
44. Shahana N., Delbello M., Chu W.J., Jarvis K., Fleck D., Welge J., et al. Neurochemical alteration in the caudate: implications for the pathophysiology of bipolar disorder. Psychiatry Research 2011, 193:107-112.
45. Maes M., Christophe A., Delanghe J., Altamura C., Neels H., Meltzer H.Y. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Research 1999, 85:275-291.
46. Adams P.B., Lawson S., Sanigorski A., Sinclair A.J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996, 31:S157-S161.
47. Edwards R., Peet M., Shay J., Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders 1998, 48:149-155.
48. Maes M., Smith R., Christophe A., Cosyns P., Desnyder R., Meltzer H.J. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. Journal of Affective Disorders 1996, 38:35-46.
49. Peet M., Murphy B., Shay J., Horrobin D.F. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological Psychiatry 1998, 43:315-319.
50. Chiu C.C., Huang S.Y., Su K.P., Lu M.L., Huang M.C., Chen C.C., et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. European Journal of Neuropsychopharmacology 2003, 13:99-103.
51. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research 1995, 29:141-152.
52. Su K.P., Leu S.J., Yang Y.Y., Shen W.W., Chou Y.M., Tsai S.Y. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. Journal of Affective Disorders 2002, 71:205-209.
53. Tsai S.Y., Chen K.P., Yang Y.Y., Chen C.C., Lee J.C., Singh V.K., et al. Activation of indices of cell-mediated immunity in bipolar disorder. Biological Psychiatry 1999, 45:989-994.
54. Tsai S.Y., Yang Y.Y., Kuo C.J., Chen C.C., Leu S.J. Effects of symptomatic severity on elevation of plasma soluble IL-2 receptor in bipolar mania. Journal of Affective Disorders 2001, 64:185-193.
55. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. Journal of Neurochemistry 2001, 77:796-803.
56. Greiner R.S., Catalan J., Moriguchi T., Salem N. Docosapentaenoic acid does not completely replace DHA in n-3 FA-deficient rats during early development. Lipids 2003, 38:431-435.
57. Salem N., Loewke J., Catalan J., Moriguchi T. Nonreciprocal replacement of docosahexaenoic acid in the rat retina. Experimental Eye Research 2005, 81:655-663.
58. Moriguchi T., Loewke J., Garrison M., Catalan J.N., Salem N. Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. Journal of Lipid Research 2001, 42:419-427.
59. Ralph-Williams R.J., Paulus M.P., Zhuang X., Hen R., Geyer M.A. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biological Psychiatry 2003, 53:352-359.
60. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:1982-1987.
61. Machado-Vieira R., Kapczinski F., Soares J.C. Perspectives for the development of animal models of bipolar disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 2004, 28:209-224.
62. Staner L., Hilger C., Hentges F., Monreal J., Hoffmann A., Couturier M., et al. Association between novelty-seeking and the dopamine D3 receptor gene in bipolar patients: a preliminary report. American Journal of Medical Genetics 1998, 81:192-194.
63. Young J.W., Minassian A., Paulus M.P., Geyer M.A., Perry W. A reverse-translational approach to bipolar disorder: rodent and human studies in the behavioral pattern monitor. Neurosciences and Biobehavioral Reviews 2007, 31:882-896.